How U.S. Pharma Executives Are Accelerating China's Dominance in Biotech and Drug Development
In just three years, China's biopharmaceutical industry has risen from near irrelevance to dominance, with U.S. pharma leaders facilitating its growth...
In just three years, China's biopharmaceutical industry has risen from near irrelevance to dominance, with U.S. pharma leaders facilitating its growth...
Bristol Myers Squibb has partnered with China’s Hengrui Pharma in a $600 million upfront licensing deal covering over a dozen early-stage drug program...